Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s.

Slides:



Advertisements
Similar presentations
Evidence-based Public Health Interventions Robert S. Lawrence, MD Bloomberg School of Public Health Johns Hopkins University April 20, 2005.
Advertisements

CANCER SCREENING 2011 DELAWARE CANCER EDUCATION ALLIANCE STEPHEN S. GRUBBS, M.D. HELEN F. GRAHAM CANCER CENTER DELAWARE CANCER CONSORTIUM OCTOBER 5, 2011.
Breast cancer chemoprevention in the high-risk patient
Which of the following increases a women’s risk for Breast Cancer? A.Starting her menses at age 14 or older B.Breastfeeding C.Extremely dense breast tissue.
†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
BREAST CANCER SCREENING Anoop Agrawal, M.D.. NEW USPSTF BREAST SCREENING GUIDELINES Published by US Preventative Screening Task Force in November 2009.
Study of Tamoxifen and Raloxifene (STAR): Initial Findings from the NSABP P-2 Breast Cancer Prevention Study D.L. Wickerham, J.P. Costantino, V. Vogel,
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
Breast Density A patient guide.
Hereditary Factors in Breast Cancer
Why can’t we prevent breast cancer? Actually, we can … The treatment can be worse than the disease – The preventative can be worse than the risk Topics.
Role of MRI in Breast Cancer Angela Kong Princess Margaret Hospital.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Cardiovascular Disease in Women Module VI: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators (SERMs)
Geriatric Health Maintenance: Cancer Screening Linda DeCherrie, MD Geriatric Fellow Mount Sinai Hospital.
Breast Imaging Made Brief and Simple
© Open University Press, 2004 Overview Prevention and screening Psychological predictors of screening The ethics and usefulness of screening? Psychological.
Midlife Women’s Health Margery Gass, MD, NCMP Executive Director The North American Menopause Society Consultant, Cleveland Clinic Center for Specialized.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Screening Tests for Brest & Cervical Cancer
Breast cancer screening Mammography is the most widely used screening modality, with solid evidence of benefit for women aged 40 to 74 years Clinical breast.
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
Hormonal Replacement Therapy for postmenopausal females: To give or not to give? Amna B. Buttar, MD, MS Assistant Professor of Clinical Medicine Indiana.
CURRENT NATIONAL PREVENTIVE HEALTH CARE GUIDELINES Juanita Halls, M.D. Professor of Medicine General Internal Medicine University of Wisconsin - UW Health.
Atoosa Adibi MD. Department of Radiology Isfahan University Of Medical Sciences.
1 Study of Tamoxifen and Raloxifene STAR Larry Wickerham, MD NSABP STAR Project Officer.
Clinical Utility of BRCA Testing Mark Robson, MD September 7,
Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.
Slide Source: Lipids Online Slide Library Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608.
Canadian Task Force on Preventive Health Care:
Breast cancer screening Diana Sarfati Director, Cancer Control and Screening Research Group.
Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Shiva Sharma SHO to Professor Redmond.  Introduction  Increased risk groups  Consideration of genetic testing  Management of patients with mutation.
FDA Presentation ODAC Meeting July NDA Applicant: Eli Lilly Evista ® (Raloxifene Hydrochloride)
HW215: Models of Health & Wellness Unit 7: Health and Wellness Models Geo-political Influences.
By: Erin Hutzell. Background: Breast Cancer Second leading cause of death due to cancer among women in in 3 women diagnosed with cancer is diagnosed.
In The Name of God BREAST IMAGING N. Ahmadinejad Medical Imaging Center TUMS.
Introduction to Healthcare and Public Health in the US The Evolution and Reform of Healthcare in the US Lecture b This material (Comp1_Unit9b) was developed.
During this presentation the learner will be able to: 1. Understand current breast cancer screening guidelines for mammography. 2. Compare and contrast.
Breast Cancer Prevention Art or Science? Kristi McIntyre M.D. Texas Oncology 2005.
BREAST CANCER: Half a million women later… Amy Miglani M.D September 3, 2004.
STAR. 2 NSABP P-1 Trial Results: Age > 50 Category TamoxifenPlacebo ARD RR(95% CI) n 4010 IR n 4008 IR Breast Cancer Invasive Invasive Non-invasive Non-invasive
Screening of genital cancers Evidence Based Presented by Dr\ Heba Nour.
Kevin S.Hughes, MD, FACS Co-Director, Avon Comprehensive Breast Evaluation Center Massachusetts General Hospital Surgeon The Newton-Wellesley Hospital.
1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.
Breast Density: Black, White and Shades of Gray Jen Rusiecki, MD VA Pittsburgh Health System Women’s Health Fellow AMWA Hot Topic 2016.
Chemoprevention of cancer Dr Manal Kahwaji Cancer fighting day Feb 2, 2016.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Practical Issues in Counseling Healthy Women About.
Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation.
© Copyright Annals of Internal Medicine, 2016 Ann Int Med. 164 (6): ITC6-1. In the Clinic Breast Cancer Screening and Prevention.
Date of download: 6/27/2016 From: Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer Ann Intern Med.
How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.
Cancer Screening Guidelines
Indications for Breast MR Imaging
Mammograms and Breast Exams: When to start /stop mammograms
Breast Cancer Screening/Imaging
JOURNAL OF CLINICAL ONCOLOGY 25:
Definition of Cancer Screening
2017 USPSTF Draft Recommendations for Prostate Cancer Screening
Breast Screening and Risk Assessment
Breast Health Katherine B. Lee, MD, FACP April 26, 2018.
Breast Imaging Ravi Adhikary, MD.
Prostate Cancer Screening- Update
Contemporary Evidence-Based Guidelines
Stamatia Destounis, MD, FACR, FSBI, FAIUM
Component 1: Introduction to Health Care and Public Health in the U.S.
Diagnosis of breast cancer in women age 40 and younger: Delays in diagnosis result from underuse of genetic testing and breast imaging 95% of patients.
imaging modalities for Breast screening
Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes Mammography screening.
Presentation transcript:

Prevention and Early Detection of Breast Cancer: Weighing the Risks and Benefits Kathy J. Helzlsouer, M.D., M.H.S. Prevention and Research Center, Women’s Center for Health and Medicine, Mercy Medical Center and The George W. Comstock Center for Public Health Research and Prevention, Hagerstown, Bloomberg School of Public Health,

Outline Prevention of Breast Cancer  Consideration of Risks and Benefits New Screening Modalities – the role of MRI

U. S. Preventive Services Task Force convened by the U.S. Public Health Service Overseen by The Center for Practice and Technology Assessment (CPTA), Agency for Healthcare Research and Quality (AHRQ) Publishes the Guide to Clinical Preventive Services – now online

Chemoprevention of Breast Cancer USPSTF Recommendations The USPSTF recommends that clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention. Clinicians should inform patients of the potential benefits and harms of chemoprevention. B recommendation. Based on fair evidence that treatment with tamoxifen can significantly reduce the risk for invasive estrogen-receptor-positive breast cancer in women at high risk for breast cancer and that the likelihood of benefit increases as the risk for breast cancer increases.. The USPSTF concluded that the balance of benefits and harms may be favorable for some high-risk women but will depend on breast cancer risk, risk for potential harms, and individual patient preferences.  All women 2.5

Chemoprevention of Breast Cancer U.S. Preventive Services Task Force The U.S. Preventive Services Task Force (USPSTF) recommends against the routine use of tamoxifen or raloxifene for the primary prevention of breast cancer in women at low or average risk for breast cancer D recommendation. The USPSTF found fair evidence that tamoxifen and raloxifene may prevent some breast cancers in women at low or average risk for breast cancer, based on extrapolation from studies of women at higher risk …. however, the potential harms of chemoprevention may outweigh the potential benefits in women who are not at high risk for breast cancer.

Definition of High Risk? Entry Criteria for the Breast Cancer Prevention Trials: who is at “high risk”? 5 year risk of breast cancer of at least 1.66%

Chemoprevention of Breast Cancer Options for High Risk Women Chemoprevention with SERMs (e.g. tamoxifen (FDA approved indication) Participation in trials using aromatase inhibitors Early phase trials using Cox 2 inhibitors

Balancing Risks and Benefits Benefits Risks

The Benefits

BCPT Results: Cumulative Rate of Invasive Breast Cancer Placebo Tamoxifen Placebo Tamoxifen Events Rate per 1000 Rate/1000 P < Years Adapted from Fisher et al. J Natl Cancer Inst 1998;90:

Benefits of tamoxifen from the BCPT Breast cancer RR  Invasive 0.5  In-situ 0.5 Hip fracture 0.55 Colles/spine fx 0.7

The Risks

BCPT Quality of Life Data Vaginal discharge Cold sweats Genital itching Night sweats Hot flashes Pain with intercourse PlaceboTamoxifenSymptom Risk Ratio % Day et al. J Clin Oncol 1999 (under submission).

Risks of tamoxifen from the BCPT Endometrial Cancer RR  Women > Stroke 1.6 DVT1.6 Pulmonary embolus3.0 Cataracts1.14

Annual incidence of adverse health events in a community-based cohort among women 40 to 70 years old compared to rates for women on the placebo arm, BCPT Rate per 1000 Stroke TIADVTEndometrial CA HipSpineColles’ Fractures

Number needed to treat to prevent

Number Needed to Treat with Tamoxifen for Harm, Per Year Number Needed Number Needed RR (BCPT) BCPT in Community Endometrial Cancer Stroke Deep Vein Thrombosis Cataracts

Number Needed to Treat with Tamoxifen for Benefit, Per Year Number Needed Number Needed RR (BCPT) Based on BCPT in Community Invasive Breast Cancer Fractures Hip Spine Colles

Aspirin for the primary prevention of cardiovascular events: Who is at high risk? 10 year risk of coronary heart disease of at least 10 %

Challenge in cancer prevention: Treat many to prevent few Breast cancer cases among 200 women with 5 year breast cancer risk of 4.0%

Benefit/risk index associated with tamoxifen for 200 white women (age range 50 to 59) with a 5 yr breast cancer risk of 4.0%

Benefit/risk index associated with aspirin use for 200 individuals With a 4% 5 yr risk of coronary heart disease

Mammography Ultrasound MRI Imaging Modalities for the Early Detection of Breast Cancer

Magnetic Resonance Imaging (MRI) Provides information on vasuclarity Higher sensitivity but lower specificity (more false positives) Not affected by breast density Evaluated in women at high risk of breast cancer (BRCA1/2 mutation carriers) where screening begins at younger ages

63 y.o. BRCA2 mutation carrier: Mammogram BI-RADS 1; MRI 3.4 cm DCIS (arrows)

Surveillance of BRCA1/2 mutation carriers with MRI, US, mammography and CBE Warner et al JAMA 292: women screened with all modalities 22 cancers detected (any suspicious (BI-RADS 4 or 5) lesions were biopsied)

Sensitivity Specificity MRI77.0% 95.4% Mammogrpahy36.0%99.8% Ultrasound33.0%96.0% CBE9.1% 99.3% Warner et al JAMA 2004; 292:

MRI, Mammography, CBE among women with a familial of genetic predisposition Kriege et al NEJM 2004;351: women; 358 crreriers of BRCA1/2 mutations 51 breast tumors; 44 invasive breast cancers Biopsy or cytology for any BI-RADS 4 or 5; BI-RADS 3 – additional examinations (US or repeat MRI)

Sensitivity Specificity MRI 71.1% 89.8% Mammogrpahy 40.0% 95.0% CBE 17.8% 98.1% Kriege et al NEJM 2004; 292: Sensitivity and Specificity for detecting invasive and non-invasive breast cancer

Who should consider having BREAST MRI in conjunction with mammogrpahy? Women at high risk – documented or suspected genetic predisposition (high prevalence improves predictive value of positive test BC/BS Technology Assessment – supports the rationale for MRI screening of BRCA mutation carriers and others at high hereditary risk Concerns –  high false positive  Translation of research findings to all clinical settings  Determining what to biopsy  Cost

Balancing Risks and Benefits Benefits Risks

The Perils of Prevention By SHANNON BROWNLEE NY Times Magazine 3/16/03